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Abstract
Introduction Arginine vasopressin (AVP) is increasingly used to
restore mean arterial pressure (MAP) in low-pressure shock
states unresponsive to conventional inotropes. This is potentially
deleterious since AVP is also known to reduce cardiac output by
increasing vascular resistance. The effects of AVP on blood flow
to vital organs and cardiac performance in a circulation altered
by cardiac ischemia are still not sufficiently clarified. We
hypothesised that restoring MAP by low dose, therapeutic level
AVP would reduce vital organ blood flow in a setting of
experimental acute left ventricular dysfunction.
Methods Cardiac output (CO) and arterial blood flow to the
brain, heart, kidney and liver were measured in nine pigs using
transit-time flow probes. Left ventricular pressure-volume
catheter and central arterial and venous catheters were used for
haemodynamic recordings and blood sampling. Transient left
ventricular ischemia was induced by intermittent left coronary
occlusions resulting in a 17% reduction in cardiac output and a
drop in MAP from 87 ± 3 to 67 ± 4 mmHg (p < 0.001). A low-
dose therapeutic level of AVP (0.005 U/kg/min) was used to
restore MAP to pre-ischemic values (93 ± 4 mmHg).
Results AVP further impaired systemic perfusion (CO and brain,
heart and kidney blood flow reduced by 29, 18, 23 and 34%,
respectively) due to a 2.0-, 2.2-, 1.9- and 2.1-fold increase in
systemic, brain, heart and kidney specific vascular resistances.
The hypoperfusion induced by AVP was associated with an
increased systemic oxygen extraction. Oxygen saturation in
blood drawn from the great cardiac vein fell from 29 ± 1 to 21
± 3% (p = 0.01). Finally, these effects were reversed 40 min
after AVP was withdrawn.
Conclusion Low dose AVP induced a pronounced reduction in
vital organ blood flow in pigs after transient cardiac ischemia.
This indicates a potentially deleterious effect of AVP in patients
with heart failure or cardiogenic shock due to impaired coronary
perfusion.
Introduction
Synthetic arginine vasopressin (AVP) has been increasingly
used to restore systemic blood pressure in low pressure shock
states unresponsive to conventional inotropes [1,2]. The asso-
ciation found between low plasma AVP levels and advanced
vasodilatory shock has given a rationale for administrating this
hormone in septic shock and in systemic inflammatory
response syndrome (SIRS) [1-4]. AVP has also been given to
patients in post-cardiotomy cardiac failure [1] and in cardio-
genic shock complicating myocardial infarction [5]. Interest-
ingly, the modulating effect of AVP on cardiac index (CI)
seems to lower CI in hyperdynamic patients whereas an eleva-
tion of CI has been found in hypodynamic patients [6]. AVP
treatment in patients with low or normal CI is however contro-
versial, since experimental studies [7-9] and small clinical trials
[10-13] have shown that the hormone may compromise car-
diac output and organ perfusion due to its vasoconstrictive
effect.
The response in vital organ perfusion, that is, pulmonary, cor-
onary and cerebral circulation, to AVP-infusions is still insuffi-
ciently clarified [14]. From its basic physiological effect on V1-
receptor stimulation in vascular smooth muscle [14], one
would predict an overall vasoconstrictive effect after AVP infu-
sion. However, infusion of the drug has been found to dilate
the coronary, pulmonary and vertebrobasilary arteries [14,15].Page 1 of 10
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AVP in a dose at therapeutic level in pigs after transient car-
diac ischemia would reduce coronary, cerebral, renal and total
organ blood flow (cardiac output). As the treatment with AVP
after cardiac ischemia is potentially the most deleterious of
conditions if vasoconstrictive in vital organs, we elected to
assess the vascular response after reperfusion of an ischemic
condition in the pig heart.
Materials and methods
Animals
The experimental protocol was approved by the local steering
committee of the National Animal Research Authority (NARA).
Nine castrated male domestic pigs (cross breed of Norwegian
Landrace and Yorkshire pigs) weighing 30 ± 1 kg were
adapted to the animal department for 5–7 days and fasted
overnight before the experiment with free access to water.
Instrumentation
The animals were pre-medicated with intramuscular injections
of 20 mg/kg ketalar (Pfizer AS, Norway) and 1 mg atropine
(Nycomed Pharma, Norway). Anaesthesia was induced by
intravenous injection of 10 mg/kg pentobarbital-sodium
(Abbott, Sweden) and 0.01 mg/kg fentanyl (Hameln Pharma-
ceuticals, Germany), and the animals were normoventilated
after tracheotomy. A central venous catheter was placed
through the left internal jugular vein, and anaesthesia was
maintained throughout the experiment using a continuous infu-
sion of 4.0 mg/kg/h pentobarbital-sodium, 0.02 mg/kg/h fen-
tanyl and 0.3 mg/kg/h midazolam (B. Braun, Melsungen,
Germany). The circulating volume was maintained by a 20 ml/
kg/h continuous infusion of 0.9% NaCl supplemented with
1.25 g/l glucose. The animals received 2 500 IU heparin, and
5 mg/kg amiodarone (Sanofi-Synthelabo, Sweden) to avoid
blood clotting of catheters and cardiac arrhythmias. Central
venous pressure (CVP) was monitored through the right jugu-
lar vein. Measurement of mean arterial pressure (MAP) and
arterial blood sampling in the abdominal aorta was performed
through a catheter inserted through the left femoral artery.
After sternotomy, the left hemiazygos vein was ligated to avoid
return of systemic blood to the coronary sinus. Transit time
flow probes (CardioMed CM-4000, Medi-Stim AS, Horten,
Norway) were placed on the left anterior descending coronary,
the right carotid artery and the pulmonary artery in order to
measure changes in coronary blood flow, cerebral blood flow
and cardiac output, respectively. A 7 Fr balloon catheter was
introduced to the inferior caval vein for preload reduction. Also,
a 7 Fr dual field, combined pressure-conductance catheter
(CD Leycom, Zoetermeer, the Netherlands) was inserted into
the left ventricular cavity via the left carotid artery for measure-
ments of left ventricular pressure and volume (P-V). Assess-
ment of the individual segments of the pressure-volume loops
confirmed the proper placement of the catheter. Myocardial
venous blood was drawn from a catheter placed in the great
cardiac vein via the coronary sinus. A catheter was inserted
into the main pulmonary trunk through the right ventricular wall
for measurement of mean pulmonary artery pressure (MPAP)
and central venous oxygen saturation (sVO2). Thereafter, a
midline laparotomy was performed and the urine bladder was
catheterised via a cystotomy. Transit time flow probes were
placed on the main hepatic artery and left renal artery in order
to measure liver and kidney blood flow, respectively. The ani-
mals were allowed to rest for 1 h before baseline
measurements.
Experimental protocol
Full data sets were collected five times during a complete
experiment. Baseline values were recorded 1 h after the end
of instrumentation. The ischemia/reperfusion protocol was
then implemented during the next 30–50 min (see below).
Post-ischemic values were recorded 40 min after the end of
the ischemia/reperfusion protocol. The pigs were subse-
quently given 0.005 U/kg/min AVP for 40 min as an initial dose
(in a series of pilot experiments this was found to be the lowest
dose necessary to restore blood pressure to pre-ischemic val-
ues). The third recordings were then performed (AVP-initial).
Thereafter, the AVP infusion rate was individually adjusted to
keep the mean arterial pressure stable at approximately 90
mmHg. The fourth measurements (AVP-90 mmHg) were car-
ried out 40 min into the infusions of this individual AVP dose.
Finally, the AVP was withdrawn and the last measurements
(Withdrawal) were performed 40 min thereafter. Obtaining
each data set required approximately 3 min and the samples
were carried out in the following order: 1, blood sampling from
femoral artery, pulmonary artery and great cardiac vein; 2,
blood oxygen levels from femoral artery (arterial or artO2 sat),
pulmonary artery (central venous or SVO2) and great cardiac
vein (sinus coronarius or sin cor O2 sat); 3 the respirator was
then disconnected for 10 s to avoid pressure influence on
haemodynamics, and steady state P-V data, MAP, MPAP,
CVP, carotid artery flow, renal artery flow, LAD flow, hepatic
and pulmonary artery flows were recorded. After a further
period of 1 min, the respirator was disconnected for another
10 s and the balloon catheter in the inferior caval vein was
inflated to obtain P-V data during vena cava occlusions (VCO)
in accordance with previous protocols from our laboratory
[16].
Ischemia reperfusion protocol
The ischemia reperfusion protocol has in principle been
described previously [17]. The present modified protocol was
based on repeated coronary occlusions to induce an acute
impairment of cardiac performance, and aimed to reversibly
reduce the flow in the larger part of the left ventricle but to
avoid the arrhythmias and pump failure connected to pro-
longed coronary occlusions. To create coronary flow perturba-
tions, rubber bands were looped around the LAD and
circumflex coronary arteries. The bands were tightened suffi-
ciently to demonstrate zero flow in the LAD signal during
occlusions. The protocol was initiated by two occlusion peri-Page 2 of 10
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occlusions were guided by a maximum occlusion time of 120
s or were terminated if MAP fell below 30 mmHg during occlu-
sions. The reperfusion time between occlusions were 30–120
s with the next occlusion starting at the onset of maximal
hyperaemia. The cumulative ischemic time was 20 ± 4 min,
and was terminated when MAP recovered to only 90% of
baseline. This protocol resulted in a slightly more pronounced
post-ischemic hypotension compared to our previous study
[17]. In four pigs, defibrillation was necessary to resuscitate
ventricular arrhythmias occurring during the LAD/CX
occlusions.
Biochemical analyses
Blood gases and base excess were immediately analysed on
a blood gas analyser (Rapid lab, Chiron Diagnostics, Emery-
ville, CA, USA). Blood samples for the other analyses were put
on ice, quickly centrifuged and plasma was then frozen.
Plasma lactate levels were determined on a biosensor (ABL
800, Radiometer, Bergman Diagnostica, Lillestrom, Norway),
while troponin T was measured by electrochemiluminiscense
(Modular E, Roche, Diagnostics, Basel, Switzerland). Plasma
AVP was analysed using an immunoassay kit (Assay Designs,
Ann Arbor, MI, USA). Sampling, preparation and analysis of
plasma catecholamines were carried out as previously
described [18,19] with minor modifications. Noradrenaline
and adrenaline were separated by HPLC (Dionex P680,
Dionex ASI-100, Chromsystems analytical column and eluent)
and their concentrations determined with an electrochemical
detector (ESA Coulochem III).
Calculation of haemodynamic indices
Vascular resistance in various systemic beds were calculated
as the pressure drop (MAP-CVP) divided by the arterial blood
flow to the respective organs. Data from the pressure-volume
catheter was analysed on CircLab (GTX Medical Software,
Zoetermeer, the Netherlands) to obtain various indices of ven-
tricular function. Calibration and practical use of the left ven-
tricular P-V catheter has been described in detail previously
[16]. Absolute volume assessment by the conductance tech-
nology requires an estimate of parallel conductance. This is
performed by hypertonic saline infusion. In the present study,
injection of hypertonic NaCl was not employed since a hyper-
tonic coronary flush could influence the coronary response to
AVP in the experimental protocol. Calculations of absolute
ventricular volumes were therefore not performed. Such calcu-
lations would have demanded an alternate technique such as
echocardiography.
The first derivative of ventricular pressure (dP/dt) was
recorded as maximum and minimum values. The time-constant
of isovolumic relaxation (Tau) was calculated according to Mir-
sky [20]. The slope of EDPVR and ESPVR denotes the line
drawn through the end diastolic and end systolic pressure vol-
ume relationship for a family of PV-loops obtained during an
abrupt vena cava occlusion [21]. The preload recruitable
stroke work index (PRSWi) integrates the systolic and diasto-
lic performances as the relation between stroke work (SW)
and end diastolic volume (EDV).
Statistics
The data are expressed as mean ± SEM. A one-way repeated
measures analysis of variance (ANOVA), followed by the
Holm-Sidak test, were used to determine differences in the
series of interventions. Data obtained 40 min after the
ischemia/reperfusion protocol were regarded as reference
value. We labelled significant differences between all data
points as compared to this reference value. In addition, we
labelled significant differences between (AVP-90 mmHg) and
(Withdrawal). Differences between means were regarded as
statistically significant when p values were less than 0.05.
Results
Post-ischemic circulation
The repetitive ischemia/reperfusion (IR) protocol was charac-
terised by a 17% reduction in cardiac output (Figure 1). This
was solely a consequence of a pronounced reduction in stroke
volume since heart rate increased from 89 ± 7 to 114 ± 6 (p
= 0.013) (Figure 2). The fall in systemic blood pressure from
87 ± 3 mmHg at baseline to 67 ± 4 mmHg (p = 0.001) after
IR, was meditated by this reduction in CO since vascular
resistance and central venous pressures were unaffected (Fig-
ures 2 and 3). Furthermore, LAD, carotid and hepatic arterial
blood flow dropped from 47 ± 5, 257 ± 23 and 65 ± 12 ml to
42 ± 4, 195 ± 34 and 47 ± 11 ml. This flow reduction was only
significant for carotid flow (p = 0.013). Arterial blood flow to
the kidney remained constant despite the reduced CO follow-
ing ischemia (Figure 1). In addition, systemic hypoperfusion
was evident from an increased oxygen extraction (art O2 sat-
SVO2) and a reduced base excess (Figure 4). Lactate
increased significantly only in the coronary sinus (Table 1). No
significant troponin T release occurred. Myocardial contractil-
ity was depressed by the ischemia/reperfusion protocol
shown by a drop in dP/dt max from 1 566 ± 85 mmHg/sec to
985 ± 74 mmHg/sec (p < 0.001) (Figure 5). Neither end
systolic elastance (Ees), nor pre-load recruitable stroke work
index (PRSWi) were significantly altered by ischemia (p =
0.31, p = 0.16). The reduced left ventricular function was
associated with a trend towards increase in mean pulmonary
artery pressure (20 ± 1 mmHg to 23 ± 1 after ischemia (p =
0.074) (Figure 2)). Finally, the diastolic function was modestly
affected by the ischemia/reperfusion protocol, as seen by a
reduction in dP/dt min from -1 704 ± 82 mmHg/sec to -1 172
± 78 mmHg/sec (p < 0.001). However, Tau and ventricular
compliance (EDP and EDPVR) were unaffected (Figure 5).
Effect of AVP treatment
All haemodynamic responses were evident within the first min-
utes of AVP infusion and levelled of to the new steady state
within the first 20 min. These indices remained stable duringPage 3 of 10
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strictive effect was observed in the carotid artery (delayed for
approximately 5 min; unpublished results).
Intravenous infusion of AVP caused a further drop in cardiac
output from 2.3 ± 0.2 L to 1.7 ± 0.2 L (p < 0.001). This was
an effect of the induced bradycardia since HR simultaneously
dropped from 114 ± 6 beats/min to 88 ± 6 beats/min (p =
0.004) whereas stroke volume remained unaffected (22 ± 2
ml IR versus 19 ± 2 ml AVP-initial, not significant). AVP had a
pronounced effect on systemic vascular resistance, which
increased twofold during drug administration. In fact, the vaso-
constriction caused by AVP resulted in a normalisation of sys-
temic pressure from 67 ± 4 mmHg to 93 ± 4 mmHg despite
the reduction in CO (Figure 2). AVP administration caused
vasoconstriction in several vascular beds, that is, a reduction
of flow in LAD, carotid, and renal arteries of 23, 18 and 34%,
respectively (p = 0.008, p = 0.033, p = 0.001) (Figure 1). This
was not observed in the hepatic artery as the blood flow
increased from 47 ± 11 ml to 112 ± 19 ml by AVP infusion (p
= 0.002). The reduced CO and peripheral vasoconstriction
escalated the tissue hypoperfusion shown by a further reduc-
tion in SVO2 and sin cor O2 sat from 49 ± 4 and 29 ± 1% to
42 ± 4 and 21 ± 3% (p = 0.05, p = 0.012), respectively (Fig-
ure 4). The lowest measured sin cor O2 sat measured was
10% during AVP infusion. Plasma AVP increased after exoge-
nous administration of the hormone confirming an adequate
dosage to reach pharmacological levels (Table 1). Concomi-
tantly, the circulation levels of catecholamines fell in the same
timeframe. AVP had no effect on contractile function as seen
by an unaffected dP/dt max and PRSWi. The Ees value
increased from 2.8 ± 0.5 mmHg/ml to 4.3 ± 0.8 mmHg/ml (p
= 0.007). Furthermore, there was an impairment of diastolic
function induced by AVP infusion. Isovolumetric relaxation time
(Tau) increased by 48% (p < 0.001), whereas ventricular com-
pliance was reduced as evident by an increased EDP and
EDPVR (Figure 5). An individual adjustment of AVP infusion
rate guided by a MAP of 90 mmHg did not principally alter any
of the parameters.
Withdrawal of AVP
By 40 min after AVP infusion was stopped, most of the indices
had returned to pre-AVP levels (Tau, EDP, EDPVR, HR, CO,
carotid flow, LAD flow, renal flow, hepatic flow, MAP, SVO2,
sin cor O2 sat and SVR). However, base excess remained at
values comparable to AVP intervention.
Discussion
The most striking observation in the present study was an
immediate drop in coronary and renal blood flow after admin-
istering AVP. Only minutes following the onset of AVP infusion,
normal blood pressure was re-established due to a twofold
increase in SVR. This was consistent with a twofold increase
in organ specific vascular resistance in the brain, heart and kid-
ney. The increased coronary resistance induced by AVP was
similar to previous observations in vivo [7,22] and ex vivo
[23,24]. Interestingly, AVP caused a reduction in coronary
blood flow, despite an increased perfusion pressure, to such
extent that it seems to override metabolic flow regulation in the
heart. This was supported by a drop in oxygen saturation in
blood drawn from the great cardiac vein. This potentially dele-
terious effect of AVP on myocardial oxygen delivery is in line
with a previous case report [25] and studies of felypressin
infusions in dogs [7]. A partly compensatory response to the
vasoconstriction could be observed in the pigs, as the heart
rate and systemic catecholamines fell after AVP infusions.
AVP at this therapeutic level further impaired post-ischemic
blood flow to the brain and kidney by vasoconstriction of the
respective vascular beds, which is a matter of some concern.
This is somewhat in contrast to observations of similar AVP
doses in another pig model including septic shock [26]. Malay
and co-workers [26] reported a heterogenic vasoconstriction
with increased CO and carotid flow and dilated coronary arter-
ies whereas renal flow dropped compatible with our observa-
tions. The explanation for the divergent findings of AVP effects
on various systemic vascular beds is not known, and whether
the vasoactive response to AVP is fundamentally different in
sepsis and cardiac ischemia is also not clear. In our study, LAD
flow, renal flow and cardiac output fell abruptly, whereas
Table 1
Plasma levels of various metabolites and hormones
Baseline IR AVP-initial AVP-90 mmHg Withdrawal
Lactate (heart) (mM) 0.63 ± 0.12* 1.30 ± 0.26 1.12 ± 0.22 1.44 ± 0.59 1.17 ± 0.21
Lactate (mM) 0.73 ± 0.09 1.26 ± 0.30 1.36 ± 0.18 1.79 ± 0.25 1.21 ± 0.14
Troponin T (μg/L) 0.04 ± 0.02 0.22 ± 0.17 0.27 ± 0.17 0.41 ± 0.24 0.57 ± 0.40
AVP (pg/mL) 82 ± 17 63 ± 21 490 ± 63* 744 ± 178* 116 ± 31†
Epinephrine (nM) 0.33 ± 0.15 0.86 ± 0.44 0.27 ± 0.09 0.13 ± 0.06* 0.24 ± 0.10
Norepinephrine (nM) 0.81 ± 0.17 1.40 ± 0.45 0.50 ± 0.15* 0.48 ± 0.09* 0.92 ± 0.31
Plasma levels of lactate, troponin T, AVP and catecholamines were obtained at different time points in the experiment. See text for experimental 
details (n = 7–9). IR, ischemia-reperfusion; *significant difference from IR; †significant difference between (AVP-90 mmHg) and (Withdrawal).Page 4 of 10
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Flow recordings. Data in mL/min (L/min for CO) obtained at baseline, 
after ischemia/reperfusion (IR) protocol, initial AVP infusions (AVP-ini-
tial), mean pressure of 90 mmHg (AVP-90 mmHg) and after drug with-
drawal (Withdrawal) (n = 9). CO, cardiac output; carotid, right carotid 
artery; LAD, left anterior descending; Renal, left renal artery; Hepatic, 
main liver artery. *Significant difference from (AHF); †significant differ-
ence (AVP-90 mmHg) and (Withdrawal).
Figure 2
Heart rate (HR) and pressure recordings. Data obtained in mmHg at 
baseline, after ischemia/reperfusion (IR) protocol, initial AVP infusions 
(AVP-initial), mean pressure of 90 mmHg (AVP-90 mmHg) and after 
drug withdrawal (Withdrawal) (see text for details) (n = 9). MAP, mean 
arterial pressure; MPAP, mean pulmonary arterial pressure; CVP, cen-
tral venous pressure. *Significant difference from (IR); †significant dif-
ference between (AVP-90 mmHg) and (Withdrawal).Page 5 of 10
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Vascular resistance. Data in dynes/sec/cm5 are obtained at baseline, 
after ischemia/reperfusion (IR) protocol, initial AVP infusions (AVP-ini-
tial), mean pressure of 90 mmHg (AVP-90 mmHg) and after drug with-
drawal (Withdrawal) (n = 9). The values are calculated as (MAP-CVP)/
(specific organ flow). SVR, systemic vascular resistance; Carotid, spe-
cific resistance in right carotid artery; LAD, specific resistance in left 
anterior descending artery supplying left ventricle; Renal, specific 
resistance in main artery supplying left kidney; Hepatic, specific resist-
ance in main liver artery. *Significant difference from (IR); †significant 
difference between (AVP-90 mmHg) and (Withdrawal).
Figure 4
Blood gas analysis. Data obtained at baseline, after ischemia/reper-
fusion (IR) protocol, initial AVP infusions (AVP-initial), mean pressure of 
90 mmHg (AVP-90 mmHg) and after drug withdrawal (Withdrawal) (n 
= 9). Cor sinus, Venous and Arterial are (%) oxygen saturation in blood 
obtained from the main heart vein, pulmonary artery and femoral artery, 
respectively. Base excess was calculated from systemic arterial blood. 
*Significant difference from (IR); †significant difference between (AVP-
90 mmHg) and (Withdrawal).Page 6 of 10
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Indices of left ventricular function. Data obtained at baseline, after ischemia/reperfusion (IR) protocol, initial AVP infusions (AVP-initial), mean pres-
sure of 90 mmHg (AVP-90 mmHg) and after drug withdrawal (Withdrawal) (n = 9). dP/dt max and min (mmHg/sec), maximal acceleration and dec-
laration of pressure in the cardiac cycle; PRSWi (mmHg), slope of preload recruitable stroke work index; Tau (ms), time constant of isovolumetric 
ventricular relaxation; SW (ml/mmHg), stroke work; EDP (mmHg), end diastolic pressure; Ees (mmHg/ml), end systolic elastance; EDPVR (mmHg/
ml), end diastolic pressure volume relationship. All values are obtained by left ventricle pressure-volume catheter at steady state or vena cava occlu-
sions (PRSWi, Ees and EDPVR). *Significant difference from (IR); †significant difference between (AVP-90 mmHg) and (Withdrawal).Page 7 of 10
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eral minutes before the flow dropped below pre-AVP values.
This trend (a non sustained cerebral blood flow increase with
AVP) was also seen in a previous study during
cardiopulmonary resuscitation (CPR) in pigs [27]. The authors
did not, however, measure the pre-CPR blood flow in their
study, making comparisons difficult. Blood flow in the hepatic
artery increased during AVP treatment consistent with a
reduction in vascular resistance. However, portal vein blood
flow was not measured, and the total hepatic blood flow could
therefore have been reduced by the AVP infusion [28,26,29].
There has been some debate regarding the effect of AVP on
cardiac contractility. Studies in isolated hearts [30], papillary
muscle [31] and myocytes [32,33] have reported a possibly
positive inotropic effect. By contrast, studies in intact animals
have shown a general trend towards negative effects on con-
tractility [34-36]. However, a major criticism against earlier in
vivo studies has been that the use of unphysiologically high
doses of AVP may cause myocardial ischemia by coronary
vasoconstriction [36]. In the present study, with therapeuti-
cally AVP levels, AVP had no effect on cardiac contractility,
evident from unchanged dP/dt max and PRSWi. Interestingly
however, there was a diastolic dysfunction following AVP infu-
sions, evident from reduced isovolumetric relaxation (Tau) and
ventricular compliance (EDPVR and EDP). Also, the increased
EES indicate an excessive load dependence in the left ventri-
cle and a manifestation of early contractile failure [36]. These
effects are probably due to the increased afterload induced by
AVP.
We infused AVP in the lowest dose a giving a significant
response in blood pressure. This approach led to plasma lev-
els similar to what have been observed in experimental haem-
orrhagic or endotoxemic shock [14]. Also, these levels have
been observed in patients on extracorporeal circulation [37]
with no infusion of AVP. Unfortunately, in the clinical studies on
patients in cardiogenic shock indicating a beneficial effect of
AVP [6,5], no AVP levels after drug infusion were reported.
The drug levels used in these studies (3.6 U/h and 4 U/h) were
approximately five times lower compared to AVP levels used in
our experimental study. The discrepancy between the experi-
mental and clinical studies indicates that much is still unknown
about AVP levels and drug effects in different types of cardiac
related shock states [38].
Limitations
The dose of AVP used in this study was derived from a dose-
response study (0.0001 U/kg/min to 0.1 U/kg/min), and the
lowest dose giving a significantly increased MAP was chosen
for the actual protocol. Comparing this dose (0.005 U/kg/min)
to previous clinical studies, it seems that the pigs in our study
have a dose-response profile different from humans. It is there-
fore evident that the dose used in our study should not be
applied in clinical practice.
The ischemia reperfusion protocol in our study creates an
ischemic cardiac dysfunction where all haemodynamic param-
eters remain stable for several hours [17]. We used this model
to investigate the effects of AVP under stable conditions. With
regards to the clinical application of AVP in cardiogenic shock,
it would be of great interest to examine the effects of AVP in
more advanced acute heart failure. However, haemodynamic
studies in an unstable and deteriorating circulation such as
cardiogenic shock are difficult to conduct and the data equally
hard to interpret when large animal variations occur. Further
studies should be undertaken to address the role of AVP in
treatment of advanced circulatory shock though our study con-
curs with previous studies showing pronounced vasoconstric-
tive properties of AVP [7-13]. It should be mentioned that in
contrast to our experimental study, AVP is never administered
as monotherapy in patients with acute heart failure, and the
aspects of drug interactions and synergy might alter the AVP
response in multidrug treatments.
Clinical implications
The haemodynamic effects of therapeutic level AVP raise seri-
ous concerns about the therapeutic potential in patients with
attenuated organ perfusion due to acute ischemic heart failure.
The negative spiral in cardiogenic shock could possibly be
hastened by applying AVP. Therefore, the drug should as a
rule not be applied in such patients [39]. Of particular impor-
tance, the drug should be used with extreme caution in cardiac
surgical patients due to the pronounced vasoconstrictive
effect on vascular grafts [37].
Conclusion
The main observations in this study were that AVP, at thera-
peutic levels, reduces cardiac output, carotid-, renal- and myo-
cardial blood flow by increased vascular resistance after
experimental acute cardiac ischemia. This contributes to an
aggravation of systemic hypoperfusion reflected by a reduced
oxygen saturation of venous blood from systemic and heart
veins. Furthermore, infusing AVP in these dosages resulted in
an impairment of the diastolic left ventricular function, whereas
myocardial contractility was unaffected by the drug. Finally,
these effects were abolished and the pigs returned to pre-AVP
values 40 min after withdrawal of the drug.
Key messages
Vasopressin in therapeutic level impairs blood flow to the 
brain, heart and kidney in pigs with post-ischemic car-
diac dysfunction. The vasoconstriction induced by vaso-
pressin leads to an increased oxygen extraction in the 
coronary circulation. This indicates that the constrictive 
effect overrides the myocardial metabolic regulation of 
the coronary circulation.
Vasopressin has no effect on cardiac contractility, and 
vasopressin infusion hampers left ventricular diastolic 
function, probably related to an elevated afterload.Page 8 of 10
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